The goal of this clinical trial aims to explore the diagnostic efficacy and grading of prostate cancer by a novel MRI sequences such as MAGiC，OGSE,CEST,IVIM,etc.The main question it aims to answer is:
Can the novel non-contrast multiparametric MRI imaging improve the accuracy of diagnosis and grading of prostate cancer? For patients with clinical suspicion of prostate cancer, both conventional and new sequences magnetic resonance scans are conducted, with surgical or biopsy pathological results serving as the gold standard.
Patients with a high clinical suspicion of prostate cancer and elevated tPSA levels;
Patients with no prior history of other tumors;
Patients with no contraindications to MRI, including claustrophobia, presence of pacemakers, cardiac stents, or metal implants such as screws and plates.
The patient has a history of malignant tumors and has received corresponding treatment;
Prior to the MRI examination, the patient has undergone treatment for prostate cancer, including endocrine therapy, radiotherapy, etc.;
Patients who have previously undergone radical prostatectomy for prostate cancer.
Patients with clinical suspicion of prostate cancer, those who have a serum tPSA level greater than 4.0 ng/ml during outpatient examination, and patients with clinical manifestations of frequent urination, urgent urination and incomplete urination.
Case-control
Prospective
observational study
Other interventionThe researchers will conduct observations, collect data and conduct follow-ups on the participants, but will not actively alter their treatment or health conditions.
Microstructure parameters related to the OGSE sequence
CEST sequence-related numerical values
MAGIC sequence-related numerical values
IVIM sequence-related numerical values
Regular sequence-related numerical values
Click on the lead sponsor to view all of their trials.
